Top

Published in:

01-10-2012 | Research

Menthol Inhibits the Proliferation and Motility of Prostate Cancer DU145 Cells

Authors: Yongzhi Wang, Xinghuan Wang, Zhonghua Yang, Guangbin Zhu, Dong Chen, Zhe Meng

Published in: Pathology & Oncology Research | Issue 4/2012

Abstract

In recent years, the transient receptor potential melastatin member 8 (TRPM8) channel has emerged as a promising prognostic marker and putative therapeutic target in prostate cancer. We have found that forced overexpression of TRPM8 in PC-3 cells can inhibit the cell proliferation and motility probably through the TRPM8 activation. In this study, we aimed to investigate whether activating the TRPM8 channel by its selective agonist menthol can inhibit the proliferation and motility of androgen-independent prostate cancer (AIPC) with remarkable expression of TRPM8. Menthol is a naturally occurring compound, which has been widely used in cosmetics and pharmaceutical products, and also as flavoring in food. DU145 cells are androgen-independent but have a remarkable expression of TRPM8. The demonstration of the existence of TRPM8 and the absence of TRPA1 in DU145 cells provided the foundation for the following experiments, because both TRPM8 and TRPA1 are molecular targets of menthol. The outcome of MTT assay indicated that menthol inhibited the cell growth (p < 0.01). Cell cycle distribution and scratch assay analysis revealed that menthol induced cell cycle arrest at the G₀/G₁ phase (p < 0.01). Furthermore, menthol inhibited the migration of DU145 cells by downregulating the focal-adhesion kinase. So it suggests that the activation of the existing TRPM8 channels may serve as a potential and pragmatic treatment for those AIPC with remarkable expression of TRPM8, and menthol is a useful compound for future development as an anticancer agent.

Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66PubMedCrossRef

Chen Y, Clegg NJ, Scher HI (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10(10):981–991PubMedCrossRef

Rosenthal SA, Sandler HM (2010) Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 7(1):31–38PubMedCrossRef

Taplin ME (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4(4):236–244PubMedCrossRef

Damber JE, Aus G (2008) Prostate cancer. Lancet 371(9625):1710–1721PubMedCrossRef

Legrand G, Humez S, Slomianny C et al (2001) Ca²⁺ pools and cell growth. Evidence for sarcoendoplasmic Ca²⁺-ATPases 2B involvement in human prostate cancer cell growth control. J Biol Chem 276(50):47608–47614PubMedCrossRef

Thebault S, Flourakis M, Vanoverberghe K et al (2006) Differential role of transient receptor potential channels in Ca²⁺ entry and proliferation of prostate cancer epithelial cells. Cancer Res 66(4):2038–2047PubMedCrossRef

Vanoverberghe K, Vanden Abeele F, Mariot P et al (2004) Ca²⁺ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 11(3):321–330PubMedCrossRef

Skryma R, Mariot P, Bourhis XL et al (2000) Store depletion and store-operated Ca²⁺ current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol 527(Pt 1):71–83PubMedCrossRef

10.

Vanden Abeele F, Skryma R, Shuba Y et al (2002) Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell 1(2):169–179PubMedCrossRef

11.

Vanden Abeele F, Roudbaraki M, Shuba Y, Skryma R, Prevarskaya N (2003) Store-operated Ca²⁺ current in prostate cancer epithelial cells. Role of endogenous Ca²⁺ transporter type 1. J Biol Chem 278(17):15381–15389CrossRef

12.

Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca²⁺ transport. Nat Rev Cancer 7(7):519–530PubMedCrossRef

13.

Tsavaler L, Shapero MH, Morkowski S, Laus R (2001) Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61(9):3760–3769PubMed

14.

Henshall SM, Afar DE, Hiller J et al (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63(14):4196–4203PubMed

15.

Yang ZH, Wang XH, Wang HP, Hu LQ (2009) Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl 11(2):157–165PubMedCrossRef

16.

Patel T, Ishiuji Y, Yosipovitch G (2007) Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol 57(5):873–878PubMedCrossRef

17.

McKemy DD, Neuhausser WM, Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416(6876):52–58PubMedCrossRef

18.

Peier AM, Moqrich A, Hergarden AC et al (2002) A TRP channel that senses cold stimuli and menthol. Cell 108(5):705–715PubMedCrossRef

19.

Zhang L (2004) Evidence that TRPM8 is an androgen-dependent Ca²⁺ channel required for the survival of prostate cancer cells. Cancer Res 64(22):8365–8373PubMedCrossRef

20.

Valero M, Morenilla-Palao C, Belmonte C, Viana F (2010) Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch-Eur J Physiol 461(1):99–114

21.

Kim S, Nam J, Park E, Kim B, So I, Jeon J (2009) Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. BBA-Mol Basis Dis 1792(1):33–38CrossRef

22.

Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434(7034):786–792PubMedCrossRef

23.

Story GM, Peier AM, Reeve AJ et al (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819–829PubMedCrossRef

24.

Bidaux G, Roudbaraki M, Merle C et al (2005) Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr Relat Cancer 12(2):367–382PubMedCrossRef

25.

RIFM (Research Institute for Fragrance Materials, Inc.) (1975) Mutagenic evaluation of compound FDA 71–57, menthol. NTIS PB-245-444 (FDA 71–268). Unpublishee report from Food and Drug Administration, 14 January. Report Number 5713, RIFM, Woodcliff Lake, NJ, USA

26.

Bernson VSM, Pettersson B (1983) The toxicity of menthol in short-term bioassays. Chem-Biol Interactions 46:233–246CrossRef

27.

Yamamura H, Ugawa S, Ueda T, Morita A, Shimada S (2008) TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol 295:C296–C301PubMedCrossRef

28.

Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7):547–566PubMedCrossRef

29.

Pines J (1995) Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 308(Pt 3):697–711PubMed

30.

Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10(1):18–25PubMedCrossRef

31.

Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692(2–3):77–102PubMedCrossRef

Title: Menthol Inhibits the Proliferation and Motility of Prostate Cancer DU145 Cells
Authors: Yongzhi Wang
Xinghuan Wang
Zhonghua Yang
Guangbin Zhu
Dong Chen
Zhe Meng
Publication date: 01-10-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-012-9520-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Patterns of Histological Changes following Hepatic Electrolytic Ablation in an Ex-Vivo Perfused Model

Primary Esophageal Small Cell Carcinoma with Brain Metastasis and with CD56, KIT, and PDGFRA Expressions

The Plasmodium Circumsporozoite Protein, a Novel NF-κB Inhibitor, Suppresses the Growth of SW480

The Expression of High Mobility Group Box 1 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma

Mathematical Modeling of Therapeutic Strategies for Myeloid Malignancies

Lupeol, A Bioactive Triterpene, Prevents Tumor Formation During 7,12-Dimethylbenz(a)anthracene Induced Oral Carcinogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer